Literature DB >> 17541736

Myocardial ischaemia-reperfusion injury is attenuated by intact glucagon like peptide-1 (GLP-1) in the in vitro rat heart and may involve the p70s6K pathway.

Amal K Bose1, Mihaela M Mocanu, Richard D Carr, Derek M Yellon.   

Abstract

BACKGROUND AND METHODS: Glucagon Like Peptide-1 (GLP-1), one of the most potent incretin hormones, has potential beneficial actions on the ischaemic and failing heart. This study sought to further identify the mechanisms of action of GLP-1 on the ischaemic heart using an in vitro isolated perfused rat heart model of ischaemic-reperfusion injury (measuring infarct size to area of risk (%)) subjected to 35 min regional ischaemia and 2 h reperfusion. To examine the effect of intact GLP-1 we used an inhibitor of GLP-1 breakdown, Valine pyrrolidide (VP). The downstream target of phosphatidylinositol 3-kinase includes the mTOR/p70s6 kinase pathway which was pharmacologically inhibited by rapamycin. RESULTS AND
CONCLUSION: GLP-1 alone did not decrease myocardial infarction (54.4 +/- 3.1%). VP alone did not decrease myocardial infarction (52.5 +/- 4%). GLP-1 in the presence of VP produced significant reduction in myocardial infarction compared to control hearts (28.4 +/- 2.7% vs. 56.4 +/- 3.9% vs. P < 0.05). Inhibiting p70s6 Kinase with rapamycin completely abolished GLP-1 induced protection (57.1 +/- 4.9% vs. 28.4 +/- 2.7% P < 0.05). There was no detectable increase in the phosphorylated p70s6k after either 5 or 10 min of treatment with GLP-1/VP or with VP alone in comparison to control blots. In conclusion we show for the first time that the protective effects of GLP-1 are mediated by intact GLP-1 and can be inhibited by blocking the p70s6 kinase.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17541736     DOI: 10.1007/s10557-007-6030-6

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  39 in total

Review 1.  Glucagon-Like Peptide-1 and Its Class B G Protein-Coupled Receptors: A Long March to Therapeutic Successes.

Authors:  Chris de Graaf; Dan Donnelly; Denise Wootten; Jesper Lau; Patrick M Sexton; Laurence J Miller; Jung-Mo Ahn; Jiayu Liao; Madeleine M Fletcher; Dehua Yang; Alastair J H Brown; Caihong Zhou; Jiejie Deng; Ming-Wei Wang
Journal:  Pharmacol Rev       Date:  2016-10       Impact factor: 25.468

Review 2.  Cardiovascular effects of antiobesity drugs: are the new medicines all the same?

Authors:  Mauro Cataldi; Angelo Cignarelli; Francesco Giallauria; Giovanna Muscogiuri; Luigi Barrea; Silvia Savastano; Annamaria Colao
Journal:  Int J Obes Suppl       Date:  2020-07-20

3.  Mitigation of autophagy ameliorates hepatocellular damage following ischemia-reperfusion injury in murine steatotic liver.

Authors:  Nitika A Gupta; Vasantha L Kolachala; Rong Jiang; Carlos Abramowsky; Asha Shenoi; Astrid Kosters; Haritha Pavuluri; Frank Anania; Allan D Kirk
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2014-09-25       Impact factor: 4.052

Review 4.  The role of incretins in glucose homeostasis and diabetes treatment.

Authors:  Wook Kim; Josephine M Egan
Journal:  Pharmacol Rev       Date:  2008-12-12       Impact factor: 25.468

5.  Elevated circulating levels of an incretin hormone, glucagon-like peptide-1, are associated with metabolic components in high-risk patients with cardiovascular disease.

Authors:  Minako Yamaoka-Tojo; Taiki Tojo; Naonobu Takahira; Atsuhiko Matsunaga; Naoyoshi Aoyama; Takashi Masuda; Tohru Izumi
Journal:  Cardiovasc Diabetol       Date:  2010-05-14       Impact factor: 9.951

6.  Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure.

Authors:  Que Liu; Christen Anderson; Anatoly Broyde; Clara Polizzi; Rayne Fernandez; Alain Baron; David G Parkes
Journal:  Cardiovasc Diabetol       Date:  2010-11-16       Impact factor: 9.951

7.  Ischemia activates the ATF6 branch of the endoplasmic reticulum stress response.

Authors:  Shirin Doroudgar; Donna J Thuerauf; Marie C Marcinko; Peter J Belmont; Christopher C Glembotski
Journal:  J Biol Chem       Date:  2009-07-21       Impact factor: 5.157

8.  GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice.

Authors:  Mohammad Hossein Noyan-Ashraf; M Abdul Momen; Kiwon Ban; Al-Muktafi Sadi; Yu-Qing Zhou; Ali M Riazi; Laurie L Baggio; R Mark Henkelman; Mansoor Husain; Daniel J Drucker
Journal:  Diabetes       Date:  2009-01-16       Impact factor: 9.461

9.  Lack of cardioprotection from subcutaneously and preischemic administered liraglutide in a closed chest porcine ischemia reperfusion model.

Authors:  Jens Kristensen; Ulrik M Mortensen; Morten Schmidt; Peter Haubjerg Nielsen; Torsten Toftegaard Nielsen; Michael Maeng
Journal:  BMC Cardiovasc Disord       Date:  2009-07-23       Impact factor: 2.298

10.  Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice.

Authors:  Meghan Sauvé; Kiwon Ban; M Abdul Momen; Yu-Qing Zhou; R Mark Henkelman; Mansoor Husain; Daniel J Drucker
Journal:  Diabetes       Date:  2010-01-22       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.